A Study of the Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia

Overview

About this study

The purpose of this study is to understand why patients with indigestion, with or without diabetes, have gastrointestinal symptoms and, in particular, to understand where the symptoms are related to increased sensitivity to nutrients.Subsequently, look at the effects of Ondansetron on these patients' symptoms.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria - Controls:

  • Healthy male or non-pregnant, non-breastfeeding female volunteers;
  • 18-75 years old;
  • Able to provide written informed consent before participating in the study;
  • Able to communicate adequately with the investigator and to comply with the requirements for the entire study; including the willingness and ability to consume the components of the test meals.

Inclusion Criteria - Patients:

  • Symptoms of dyspepsia (i.e., early satiety, postprandial discomfort, nausea, vomiting, regurgitation);
  • Patients in the DM group will also require.

Exclusion Criteria – Patients and Controls:

  • Major abdominal surgery (i.e., appendectomy, cholecystectomy, tubal ligation,  hysterectomy, herniorrhaphy, and limited colonic resection are permissible);
  • Clinical evidence (including physical exam and EKG) of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study and/or pose safety concerns;
  • Current use of opiates, alpha adrenergic agonists, metoclopramide, monoamine oxidase inhibitors, more than one serotonergic medication, and high doses of anticholinergic agents (eg, amitriptyline greater than 50 mg daily).  If medically safe, these drugs may be discontinued for four half lives prior to study assessments; 
  • Treatment with GLP-1 agonists and amlyin which cause vagal blockade and may affect central processing of pain;
  • Bleeding or clotting disorders or medications that increase risk of bleeding from mucosal biopsies;
  • Positive tissue transglutaminase antibodies (TTG);
  • Pregnant or breast-feeding females;
  • Known intolerance or allergy to eggs;
  • Poor peripheral venous access, if central venous access is not available;
  • Any other condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study;
  • History of Long QT Syndrome or prolonged QT interval (i.e., corrected QT interval.

Exclusion Criteria - Controls:

  • Current symptoms of a functional gastrointestinal disorder assessed by questionnaire.

Exclusion Criteria - Patients:

  • Severe vomiting that would preclude tube placement or participation in the study;
  • Structural cause for symptoms by endoscopy within the past 12 months;
  • Patients with gastric pacemakers.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Adil Bharucha, M.B.B.S., M.D.

Open for enrollment

Contact information:

Amber Galbreath

(507)538-3883

Galbreath.Amber@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20452835

Mayo Clinic Footer